Lupin and Rep. Bonnie Watson Coleman (DNJ – 12th District), celebrated the grand opening of the company's 100,000 square foot expansion of its manufacturing facilities in Somerset.
"We are very pleased to officially open our new facility at Somerset,” Vinita Gupta, Chief Executive Officer of Lupin Limited, said. “This expansion enables us to serve the growing need for affordable medicines for U.S. patients, providers, government and other stakeholders. In the last three years, we have made strategic investments in the U.S. in R&D and manufacturing to establish a deeper footprint in the country, and access technology capabilities for niche technology platforms."
Since 2016, Lupin has invested over $1 billion in R&D and Manufacturing in the United States. Lupin employs 635 employees in the U.S. In March 2016, Lupin acquired the Somerset facility for $880 million. Since acquisition, approximately 80 jobs have been created to support the site bringing the total number of employees in Somerset up to 380. An additional 50 jobs are expected to be added over the next 12 to 18 months.
"The opening of this facility in Somerset enhances our scale in the U.S. generic market, and is a complement to Lupin's Coral Springs, Florida, inhalation R&D center," Lupin President Kurt Nielsen said. "We have set ambitious targets for ourselves in the U.S. market. This 10-fold expansion of our manufacturing site will enable us to meet and exceed our targets. We are confident that we will continue to grow, and look forward to creating additional opportunities which benefit our community."